A Luminex assay detects amyloid ? oligomers in Alzheimer's disease cerebrospinal fluid.

ABSTRACT: Amyloid beta (a?) protein assembles into larger protein aggregates during the pathogenesis of Alzheimer's disease (AD) and there is increasing evidence that soluble a? oligomers are a critical pathologic species. Diagnostic evaluations rely on the measurement of increased tau and decreased a?42 in the cerebrospinal fluid (CSF) from AD patients and evidence for oligomeric a? in patient CSF is conflicting. In this study, we have adapted a monoclonal single antibody sandwich ELISA assay to a Luminex platform and found that this assay can detect oligomerized a?42 and sAPP? fragments. We evaluated oligomeric a? reactivity in 20 patients with AD relative to 19 age matched controls and compared these values with a commercially available Alzbio3 kit that detects tau, phosphorylated tau and a?42 on the same diagnostic platform. We found that CSF samples of patients with AD had elevated a? oligomers compared to control subjects (p < 0.05) and the ratio of a? oligomers to a?42 was also significantly elevated (p < 0.0001). Further research to develop high sensitivity analytical platforms and rigorous methods of developing stable assay standards will be needed before the analysis of oligomeric a? becomes a routine diagnostic assay for the evaluation of late onset AD patients.

SUBMITTER: Herskovits AZ 

PROVIDER: S-EPMC3699502 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature